Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A.
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is a putative tumor suppressor whose expression can be increased by drug treatment. Glioblastoma is the most common central nervous system tumor, is associated with high morbidity and mortality, and responds poorly to surgical, chemical, and radiation therapy. The histone deacetylase inhibitors are under current consideration as therapeutic agents in treating glioblastoma. We investigated whether trichostatin A (TSA) would alter the expression of NAG-1 in glioblastoma cells. The DNA demethylating agent 5-aza-dC did not increase NAG-1 expression, but TSA up-regulated NAG-1 expression and acted synergistically with 5-aza-dC to induce NAG-1 expression. TSA indirectly increases NAG-1 promoter activity and increases NAG-1 mRNA and protein expression in the T98G human glioblastoma cell line. TSA also increases the expression of transcription factors Sp-1 and Egr-1. Small interfering RNA experiments link NAG-1 expression to apoptosis induced by TSA. Reporter gene assays, specific inhibition by small interfering RNA transfections, and chromatin immunoprecipitation assays indicate that Egr-1 and Sp-1 mediate TSA-induced NAG-1 expression. TSA also increases the stability of NAG-1 mRNA. TSA-induced NAG-1 expression involves multiple mechanisms at the transcriptional and post-transcriptional levels.
Yoshioka
Hiroki
H
Laboratory of Molecular Carcinogenesis, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, USA.
Kamitani
Hideki
H
Watanabe
Takashi
T
Eling
Thomas E
TE
D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D045744:Cell Line, Tumor; D000077209:Decitabine; D051766:Early Growth Response Protein 1 / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005909:Glioblastoma / Q000378:metabolism*; D055436:Growth Differentiation Factor 15 / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D034741:RNA, Small Interfering / Q000494:pharmacology; D016329:Sp1 Transcription Factor / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D004791:Enzyme Inhibitors; C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D034741:RNA, Small Interfering; D016329:Sp1 Transcription Factor; C012589:trichostatin A; D000077209:Decitabine; D001374:Azacitidine
J Neurosci. 2000 Dec 1;20(23):8597-603
11102463
Mol Cancer. 2007;6:36
17547775
J Comp Neurol. 2001 Oct 8;439(1):32-45
11579380
J Biol Chem. 2001 Nov 9;276(45):42084-90
11551946
J Clin Oncol. 2002 Mar 1;20(5):1375-82
11870182
Carcinogenesis. 2002 Mar;23(3):425-34
11895857
J Biol Chem. 2002 May 10;277(19):16823-30
11877441
J Pharmacol Exp Ther. 2002 Jun;301(3):1126-31
12023546
Biochem Biophys Res Commun. 2002 Jul 5;295(1):187-92
12083788
Circ Res. 2002 Nov 1;91(9):837-44
12411399
Br J Cancer. 2002 Oct 21;87(9):1042-6
12434298
Mol Pharmacol. 2003 Mar;63(3):557-64
12606762
Nucleic Acids Res. 2003 Mar 15;31(6):1693-703
12626711
Int J Cancer. 2003 Jul 20;105(6):747-53
12767058
Oncogene. 2003 Sep 4;22(38):6023-31
12955081
J Biol Chem. 2004 Feb 20;279(8):6883-92
14662774
Carcinogenesis. 2004 Oct;25(10):1813-20
15142888
J Biol Chem. 1979 Mar 10;254(5):1716-23
762168
J Biol Chem. 1993 Oct 25;268(30):22429-35
8226751
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5705-8
8650156
Nature. 1997 Sep 25;389(6649):349-52
9311776
Cell. 1998 Feb 20;92(4):463-73
9491888
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3356-61
9520369
Exp Cell Res. 1998 May 25;241(1):126-33
9633520
Nat Genet. 1999 Jan;21(1):103-7
9916800
Curr Opin Genet Dev. 1999 Feb;9(1):40-8
10072350
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
10200307
Oncogene. 1999 Apr 15;18(15):2461-70
10229197
Mol Cell Biol. 1999 Aug;19(8):5504-11
10409740
Mol Pharmacol. 2005 Feb;67(2):356-64
15509713
Biochem Biophys Res Commun. 2005 Mar 4;328(1):63-9
15670751
Acta Neuropathol. 2005 Jan;109(1):93-108
15685439
Prostate. 2008 Feb 1;68(2):210-22
18092350
Br J Pharmacol. 2008 Feb;153(4):657-68
18059320
J Cell Mol Med. 2008 Apr;12(2):607-21
18419600
Breast Cancer Res Treat. 2008 Sep;111(1):15-25
17891453
Cancer Lett. 2008 Oct 18;270(1):30-9
18550273
J Biol Chem. 2005 Sep 23;280(38):32569-77
15994313
Mol Cancer Ther. 2005 Oct;4(10):1551-8
16227405
Prog Lipid Res. 2006 Jan;45(1):1-16
16337272
Mol Cancer Ther. 2006 May;5(5):1352-61
16731769
J Pharmacol Exp Ther. 2006 Aug;318(2):899-906
16714403
Gastroenterology. 2006 Nov;131(5):1553-60
17101328
J Biochem Mol Biol. 2006 Nov 30;39(6):649-55
17129398
J Biol Chem. 2007 Feb 16;282(7):4765-71
17121856
Cancer. 2007 Apr 15;109(8):1676-88
17330857
J Biol Chem. 2001 Sep 7;276(36):33384-92
11445565